Stargardt Disease Epidemiology Forecast to 2030 by DelveInsight

Posted on
by

Stargardt Disease Epidemiology Forecast to 2030 by DelveInsight

(Albany, US) DelveInsight has launched a new report on Stargardt Disease Epidemiology

 

DelveInsight’s ‘Stargardt Disease (STGD) Epidemiology Forecast to 2030′ report delivers an in-depth understanding of the disease, historical and forecasted Stargardt Disease (STGD) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

 

Stargardt Disease (STGD) is named after Karl Stargardt, a German ophthalmologist who first reported a case in his practice in 1901. It is also called Stargardt macular dystrophy, juvenile macular degeneration, or fundus flavimaculatus. It is a rare retinal disorder inherited in an autosomal recessive pattern. Decreased central vision due to loss of photoreceptors in the macula is the hallmark of Stargardt disease. It typically develops during childhood or adolescence, but the age of onset and rate of progression can vary. Mutations in a gene called ABCA4 are the most common cause of Stargardt disease. This gene makes a protein that normally clears away vitamin A byproducts inside rods and cones (photoreceptors). Cells that lack the ABCA4 protein accumulate clumps of lipofuscin, a fatty substance that forms yellowish flecks. As the clumps of lipofuscin increase in and around the macula, central vision becomes impaired. Eventually, these fatty deposits lead to the death of photoreceptors and vision becomes further impaired.

 

View Free Sample Page:-  https://www.delveinsight.com/sample-request/stargardt-disease-stgd-epidemiology-forecast

 

Stargardt Disease Epidemiology

Stargardt disease is a form of macular degeneration, and is often called juvenile macular degeneration. Macular degeneration is when part of the retina that gives you central vision, called the macula, breaks down. In people with Stargardt disease, special light-sensing cells in the macula, called photoreceptors, die off. Central, or detailed, vision becomes blurry or has dark areas. It may also be difficult to see colors well. For most people, vision loss progresses slowly over time to 20/200 or worse.

 

Stargardt Disease key Facts

  • According to the estimates provided by National Institute for Health, the reported prevalence of Stargardt disease is estimated to be 1 in 8,000 to 10,000 individuals.
  • In a study titled “Stargardt disease: clinical features, molecular genetics, animal models and therapeutic options”, conducted by Tanna et al. (n.d.), STGD has a prevalence of 1 in 8000–10,000.
  • According to American Institute of Ophthalmology, STGD is the most commonly inherited childhood and adulthood maculopathy and has a prevalence of 1 in 10,000.
  • According to the Foundation Fighting Blindness, Stargardt disease is the most common form of inherited macular degeneration, affecting about 30,000 people in the U.S. The progressive vision loss associated with Stargardt disease is caused by the degeneration of photoreceptor cells in the central portion of the retina called the macula.
  • In a study titled “Stargardt disease: clinical features, molecular genetics, animal models and therapeutic options”, conducted by Tanna et al. (n.d.), STGD has a prevalence of 1 in 8000–10,000.
  • Results from a study titled “The Epidemiology of Stargardt Disease in the United Kingdom” conducted by Kurt Spiteri Cornish et al. (n.d.) suggested an annual incidence of Stargardt disease between 0.110 and 0.128 per 100 000 individuals.
  • According to American Macular Degeneration Foundation, “In rare cases–one in 20,000–macular degeneration is diagnosed in children and teenagers. Stargardt affects both eyes and develops sometime between the ages of six and twenty, when kids notice difficulties in reading or adapting to bright light. The cause and treatments of the disease in young people are different from those of Age-related Macular Degeneration.”

 

Stargardt Disease Report Scope

  • The Stargardt Disease (STGD) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Stargardt Disease (STGD) Epidemiology Report and Model provide an overview of the risk factors and global trends of Stargardt Disease (STGD) in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Stargardt Disease (STGD) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Stargardt Disease (STGD)
  • The report provides the segmentation of the Stargardt Disease (STGD) epidemiology

 

Download Free Sample Page:-  https://www.delveinsight.com/sample-request/stargardt-disease-stgd-epidemiology-forecast

 

Table of content

 

1. Key Insights 

2. Executive Summary of Stargardt Disease (STGD)

3. Stargardt Disease (STGD): Disease Background and Overview

4. Patient Journey

5. Epidemiology and Patient Population

6. Treatment Algorithm, Current Treatment, and Medical Practices

7. KOL Views

8. Unmet Needs

9.  Appendix

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

 

Why should you buy this report?

  • The Stargardt Disease (STGD) Epidemiology report will allow the user to –
  • Develop business strategies by understanding the trends shaping and driving the global Stargardt Disease (STGD) market
  • Quantify patient populations in the global Stargardt Disease (STGD) market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Stargardt Disease (STGD) therapeutics in each of the markets covered
  • Understand the magnitude of Stargardt Disease (STGD) population by its epidemiology
  • The Stargardt Disease (STGD) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

 

Related Reports

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/